Sub menu

 
 

ACV meeting statement, meeting 48, 1 May 2024

Advisory Committee on Vaccines
Published

Section A: Premarket registration applications

At this meeting the committee provided advice on one application under evaluation by the TGA:

Active ingredient (TRADENAME)SponsorTherapeutic areaApplication designationsCommencement of evaluation
Applications for a 'new vaccine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia (Application Type A)

respiratory syncytial virus F protein mRNA (nucleoside modified)

(Tradename to be confirmed)

Moderna Australia Pty LtdFor the prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory syncytial virus (RSV).PriorityJuly 2023

Details of the ACV advice associated with this item may be released in the Australian Public Assessment Reports (AusPARs). Browse all AusPARs. 

Section B: Post-market items

Nil item.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines. 

or contact the ACV by email ACV@health.gov.au.

Topics
Outcome of

Help us improve the Therapeutic Goods Administration site